将免疫疗法纳入B细胞前体急性淋巴细胞白血病的成年人前线治疗
Talha Badar1, Selina M Luger2, Mark R Litzow3
1Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL.
化疗免疫疗法已经改变了成人B细胞前体急性淋巴细胞白血病 (BCP-ALL) 治疗. 新型药物如布利纳图莫马布和伊诺图祖马布 (inotuzumab ozogamicin) 改善了结果,特别是在复发性/耐药性或可测量的残留病阳性BCP-ALL.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 成人B细胞前体急性淋巴细胞白血病 (BCP-ALL) 治疗结果落后于儿科病例,复发率高.
- 在老年人中,强化化疗方案的耐受性很差,导致显著的发病率和死亡率.
- 免疫疗法提供了一种有希望的途径,可以增强反应并降低复发风险,而不会增加毒性.
研究的目的:
- 审查成年人治疗B细胞前体急性淋巴细胞白血病 (BCP-ALL) 的化疗免疫疗法的演变.
- 突出新型免疫治疗剂对BCP-ALL管理的影响.
- 讨论将新药纳入前期和巩固疗法的问题.
主要方法:
- 审查最近的临床试验和研究的免疫治疗药物在BCP-ALL.
- 对利图西马布,伊诺图祖马布,奥佐加米辛,布利纳图莫马布和CAR T细胞的数据进行分析.
- 对复发性/耐药性和可测量的残留病阳性BCP-ALL的治疗策略的检查.
主要成果:
- 免疫治疗药物显著改善了复发性/耐药性BCP-ALL的结果.
- 在添加到化疗时,BLINATUMOMAB在MRD阴性第一缓解中显示了生存益处.
- 伊诺图祖马布和布利纳图祖马布的前期使用显示出有希望的结果,有或没有化疗.
结论:
- 化疗免疫疗法已经彻底改变了成人BCP-ALL治疗,提供了更好的疗效和耐受性.
- 新代理商越来越多地被纳入前期和整合战略.
- 对免疫治疗组合的持续研究有望进一步改善BCP-ALL患者的治疗结果.
更多相关视频
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
相关概念视频
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
